Polynovo's valuation gap widens as its US FDA submission timeline firms up
A broad healthcare sector sell-off pushed Polynovo to valuation lows Endeavor Asset Management called hard to reconcile with its fundamentals, before a finalised US clinical study and a firmer FDA submission timeline drove a sharp share price recovery.
31 May 2026 · 4 min read
In short
Polynovo fell to approximately 3.5 times forward EV to sales and 16 times EV to EBITDA in January 2026, well below historical averages, even as Endeavor Asset Management noted sales growth of 20-30% per annum and expanding margins.
Polynovo's Nova wound care product is differentiated from competitors such as Aroa on necrotised wounds, according to Forager Funds, which the fund said makes the products complementary rather than directly interchangeable.
Polynovo shares rose 22% in May 2026 after finalising a US clinical study supporting its premarket approval submission, with the revised timeline allowing 18-month follow-up data to be included in the final FDA package.
Polynovo Ltd (ASX: PNV) spent early 2026 trading at valuation levels its own fund manager holders described as disconnected from its underlying growth, before a US regulatory milestone reversed the mood sharply by May. Endeavor Asset Management captured the disconnect starkly in January, noting the wound care specialist's sell-off had pushed valuation to levels not previously seen, at approximately 3.5 times forward EV to sales and 16 times EV to EBITDA, well below historical averages, even as the company continued to deliver sustained sales growth of 20-30% per annum with expanding margins.
The business continues to deliver strong execution, supported by a robust pipeline and sustained sales growth of 20-30% per annum. Operating leverage remains evident, and margins are expanding. Against this backdrop, our assessment of intrinsic value remains materially above the current share price.
Endeavor Asset Management, Monthly Report, January 2026
A differentiated product in a crowded wound care market
Forager Funds addressed how Polynovo's Nova product sits relative to competitors in January 2026, noting that while Nova can be used across many different wound care applications, it is not suited for necrotised wounds, an area where peer Aroa's product remains the more appropriate choice. The fund framed this as evidence the two companies are complementary rather than directly substitutable, each serving different segments of the wound care market rather than competing head to head for the same cases.
A US regulatory catalyst reverses the narrative
The turning point arrived in May 2026, when Endeavor Asset Management reported Polynovo shares rose 22% following the finalisation of a US clinical study supporting its premarket approval submission. The fund said the revised timeline allows the company to include 18-month follow-up data in its final FDA submission package, a development it viewed as strengthening the regulatory case. Looking ahead, the fund said it expects the company to manage its cost base and increase its focus on MTX product sales as further updates and catalysts evolve from the FDA submission process, while flagging that any cost discipline could be partially offset by increased research and development spend as the product portfolio continues to evolve.
What managers are watching next
With the FDA submission timeline now firmer following the finalised clinical study, the key signposts fund managers are tracking are the actual submission of the premarket approval package incorporating the 18-month follow-up data, the pace of any further FDA-related updates, and whether cost discipline around MTX product sales can offset the anticipated increase in research and development spend as Polynovo's product portfolio continues to expand.
Questions
Why did Polynovo's valuation fall so sharply in January 2026?
Endeavor Asset Management said a broader healthcare sentiment sell-off pushed Polynovo to approximately 3.5 times forward EV to sales and 16 times EV to EBITDA, well below historical averages, despite the company continuing to deliver 20-30% annual sales growth and expanding margins.
Why did Polynovo shares rise 22% in May 2026?
Polynovo shares rose 22% after the company finalised a US clinical study supporting its premarket approval submission, with the revised timeline allowing 18-month follow-up data to be included in the final FDA submission package.
How does Polynovo's Nova product compare to competitors like Aroa?
Forager Funds notes that while Polynovo's Nova product can be used across many wound care applications, it is not suited for necrotised wounds, an area where Aroa's product remains the more appropriate choice, making the two companies' products complementary rather than directly interchangeable.
4 managers, 14 comments, with each manager's latest recorded position.
See PNV